Login to Your Account



Starpharma readies U.S. NDA for Vivagel on positive phase III results in bacterial vaginosis

By Tamra Sami
Staff Writer

Wednesday, August 9, 2017

PERTH, Australia – Melbourne-based biotech Starpharma Ltd. expects to file its rolling NDA with the FDA in the next month following positive phase III results for Vivagel BV for preventing recurrent bacterial vaginosis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription